Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carboplatin + Paclitaxel + RO4929097|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|RO4929097||RG-4733||Gamma secretase inhibitor 12||RO4929097 (RG-4733) is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 19773430, PMID: 31953695).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Carboplatin + Paclitaxel + RO4929097||Phase I||Actionable||In a Phase I trial, the combination of RO4929097 (RG-4733), Paraplatin (carboplatin), and Taxol (paclitaxel) demonstrated safety and resulted in a pathologic complete response in 36% (5/14) of patients with triple receptor-negative breast cancer; however, this trial as well as further development of RO4929097 (RG-4733) were discontinued due to the limited clinical efficacy observed in other cancer types (PMID: 31953695).||31953695|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|